SensoDetect accelerates international collaborations to advance early screening and diagnostic support tools for Autism and ADHD

SensoDetect AB (publ) today announced a new phase of international collaborations aimed at accelerating its clinical validation program for neuropsychiatric diagnostics. Over the coming months, the company will launch multiple initiatives with leading partners across the Middle East, Europe, and Asia to expand its clinical reach, demonstrate the value of its international sales and marketing plans, and build a stronger foundation for regulatory and commercial success.

Central to this strategy is the ongoing autism spectrum disorder (ASD) study in Saudi Arabia, which is being enhanced with additional resources and local partnerships. Meanwhile, SensoDetect is preparing broader data collection programs to support its next-generation ADHD algorithms, using auditory brainstem response (ABR) technology and advanced machine learning methods.

As part of these efforts, SensoDetect announced the appointment of Dr. Fatimah Saeed Alahmari as medical advisor. Dr. Alahmari’s expertise and network in the region will help optimize the Saudi Arabia autism study and facilitate the collection of new high-quality neurophysiological data for ADHD research. Her appointment highlights the company’s commitment to strengthening its presence in the Middle East and establishing long-term collaborations with key stakeholders.

“Our strategy is built on strong international collaboration,” said P-A Hedin, CEO of SensoDetect. “By partnering with experienced organizations in the Middle East and beyond, we are expanding our clinical reach and showcasing the value of our international sales and marketing plans. The engagement of Dr. Alahmari marks an important milestone in this journey, and we look forward to announcing additional partnerships in the months ahead.”

As previously announced, Dr. Mohamed Atwa, Head of Clinical Research, has relocated to Sweden to work more closely with the R&D team, ensuring seamless integration of clinical insights into algorithm development. CEO P-A Hedin will also visit Dubai in October to meet regional partners and further strengthen relationships vital for the company’s international growth.

Through these steps, SensoDetect is positioning itself as a global leader in objective, scalable, and clinically valuable early screening and diagnostic tools for neuropsychiatric disorders, driving innovation in autism and ADHD detection and paving the way for broader adoption within healthcare systems.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04
pa.hedin@sensodetect.com

SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of screening, diagnostics, medication, and health. The products are used in both private and public healthcare and schools, as a screening and complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.

More info at https://www.sensodetect.com/